Pressure mounts for BP buy-back

The Investment Column

The management at British Petroleum could well have been singing Labour's campaign anthem, "Things can only get better", as they unveiled yet another set of record profits for the first quarter yesterday. Whether or not the chairman, Sir David Simon, decides to join Tony Blair's merry band, the stock market was cheering. The share price ended 29p higher at 732.5p as analysts asked the big question: whether BP will be tempted into a more ambitious exercise to return value to investors. BP's chief executive John Browne cautiously insisted share buy-backs or special dividends were not on the immediate agenda yesterday, but with numbers like these the markets are salivating.

Progress in all directions was better than expected. Replacement cost profits before taxes and exceptional items, the best underlying measure of performance, surged by 19 per cent in sterling terms to pounds 755m, while the result in dollars was up 27 per cent, the difference reflecting the surge in sterling over the past year. The return on capital climbed to 19 per cent, the kind of figure Shell's top team would die for.

Better still, BP appears to have overcome wobbles this year about falling oil prices after the excesses of 1996, when a barrel of crude was selling for as much as $25. So far in 1997 prices have dipped to $18, which BP insisted was in line with a long-term trading range of between $16 and $19. This compares with the company's internal benchmark for investment projects of an ultra cautious $14.

Against falling prices, BP has seen even faster benefits from its self- help programme, chanted like a corporate mantra from office to office in the hunt for extra profit. To recap, the target set in 1995 was to save $1.5bn over five years from cost cutting and higher productivity, yet last year alone BP saved $600m and promptly brought forward its timetable by 12 months.

In this quarter it has saved another $120m and is hoping for even more towards the end of the year, so the internal target for 1997 of $300m looks increasingly conservative. Part of the drive behind these improvements comes from naked self-interest, as BP executives get their full personal bonuses if savings reach twice the target level.

After a dividend hike in the last quarter it was too much to hope for another one this time, though further increases in the second half are now certain. There is no constraint from borrowings, which at $6bn compare with long-term aspirations of $7bn to $8bn, but the reason Mr Browne remains cagey about raising the payout is, or course, political. Dishing out cash in special dividends or buy-backs would be a red rag to Labour as the other Mr Brown (Gordon that is) contemplates raising North Sea oil tax. Yet the pressure from the market for BP to do something by the end of the year is becoming intense.

Full-year profits of pounds 2.94bn would put the shares on a forward multiple of 14. Currently yielding 3.3 per cent and with the case for special payouts all but unanswerable, the shares are a definite hold.

Shire's portfolio

is blossoming

Shire Pharmaceuticals is putting in a strong bid to be taken seriously as more than just a biotechnology hopeful. Following on from February's chunky pounds 105m acquisition of Pharmavene, a US drugs delivery group, yesterday the group was demonstrating the breadth of its drugs pipeline in a research and development update.

Galantamine, the compound originally derived from daffodils which represents Shire's lead product, is proving to have wider medical properties than originally thought. Initially indicated for use against Alzheimer's disease, the group is now ready to test its use against chronic fatigue syndrome, also known as ME or "yuppie flu". A 300-patient trial into both efficacy and tolerability will start later this month, with another involving 60 people in Iceland due to start in September. If it ever reaches doctors' surgeries, perhaps in 2005, it could be attacking a $2.5bn market for which there is no current treatment, the company believes. But there is more, for early observations using galantamine against Alzheimer's appear to show it is effective against both rheumatoid arthritis and osteoarthritis, two other big markets.

Meanwhile, analysts are excited by the prospects for Lambda, a treatment for reducing phosphate levels in the blood of people with kidney disease. Untreated, a build up of phosphate can lead to bone disease. Shire is already the market leader in the UK in this area with its calcium carbonate product, but Lambda is said to offer substantial improvements. The potential market is 1.6 million patients world-wide and this could be the first drug to be marketed outside the UK directly by Shire.

Finally, Shire reckons Nifedipine SR, a cardiovascular which could be launched before 2000, might sell into a US market worth $1.1bn. That will depend, however, on whether it can overcome expected legal action from Pfizer, the current market leader.

The wide portfolio at Shire is matched by the depth of its management. Much still depends on the outcome of the phase III tests for the Alzheimer's drug, due in September, but Lehman Brothers estimate the shares' net present value at 274p, rising to 364p next year. That is below the current market price of 219p, up 2p, and makes them a reasonable punt.

Sidlaw repackages its strategy

Sidlaw has been through the wars since its disastrous 1993 decision to step up the scale of its flexible packaging operations. That led to losses over the past two years and a plunging share price, but John Durston, who took over as chief executive in the autumn, is starting to use his experience in the industry to good effect.

Last year's move to dump the oil services business took the decision to concentrate on packaging to its logical conclusion. But Mr Durston has also put a lot of effort into improving customer service and efficiency, two areas which appeared neglected under the dash for volume policy which led Sidlaw astray before. The fruits of these labours are reflected in the group's half-year results to March, although the figures are distorted by the pounds 17.3m profit on the sale of oil services and a pounds 1.7m charge for rationalisation.

Stripping that lot out, the underlying pre-tax total rose from a loss of pounds 1.41m to a profit of pounds 1.75m.

The proceeds of the disposal of oil services cut the interest charge from pounds 2.09m to pounds 162,000 and left net cash of pounds 3.3m in March. The group reckons it has firepower for pounds 25m of acquisitions, but nothing is imminent. In the meantime, it will be pushed into borrowings again by a pounds 12m capital expenditure programme this year.

Part of the spending will help service a pounds 6m-a-year contract to supply Cadbury with wrappers and should also improve efficiency. Sidlaw also claims to have won back most of the customers lost during its difficult patch.

The problem remains, however, that the group is still highly dependent on mature or declining markets like biscuit packets and bread bags, which remain at the mercy of the supermarket price wars. Even with innovative products like its P-Plus "breathable" fresh-produce wrapper, it still has to prove it is not just running to stand still.

Profits of pounds 3.5m in the full year would put the shares, down 3p at 103.5p, on a forward p/e of 23. The shadow of previous rights issues at 275p and 180p hangs over the shares, but they are probably still worth holding.

Start your day with The Independent, sign up for daily news emails
News
Young Winstone: His ‘tough-guy’ image is a misconception
people
Sport
Adnan Januzaj and Gareth Bale
footballManchester United set to loan out Januzaj to make room for Bale - if a move for the Welshman firms up
Arts and Entertainment
Ellie Levenson’s The Election book demystifies politics for children
bookNew children's book primes the next generation for politics
News
Outspoken: Alexander Fury, John Rentoul, Ellen E Jones and Katy Guest
newsFrom the Scottish referendum to the Ice Bucket Challenge, our writers voice their opinions
PROMOTED VIDEO
News
i100
Sport
Yaya Sanogo, Mats Hummels, Troy Deeney and Adnan Januzaj
footballMost Premier League sides are after a striker, but here's a full run down of the ins and outs that could happen over the next month
Arts and Entertainment
L to R: Hawkeye (Jeremy Renner), Captain America (Chris Evans) & Black Widow (Scarlett Johansson) in Avengers Assemble
film
News
Nigel Farage celebrates with a pint after early local election results in the Hoy and Helmet pub in South Benfleet in Essex
peopleHe has shaped British politics 'for good or ill'
Arts and Entertainment
Pharrell Williams' “Happy” was the most searched-for song lyric of 2014
musicThe power of song never greater, according to our internet searches
Sport
Tim Sherwood raises his hand after the 1-0 victory over Stoke
footballFormer Tottenham boss leads list of candidates to replace Neil Warnock
ebooks
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Arts and Entertainment
Sink the Pink's 2013 New Year's Eve party
musicFour of Britain's top DJs give their verdict on how to party into 2015
Voices
Strictly Come Dancing was watched by 6.9m viewers
voicesIt has been hard to form generally accepted cultural standards since the middle of the 19th century – and the disintegration is only going to accelerate, says DJ Taylor
Arts and Entertainment
Roffey says: 'All of us carry shame and taboo around about our sexuality. But I was determined not to let shame stop me writing my memoir.'
books
News
i100
News
Caplan says of Jacobs: 'She is a very collaborative director, and gives actors a lot of freedom. She makes things happen.'
people
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Selby Jennings: VP/SVP Credit Quant- NY- Investment Bank

Not specified: Selby Jennings: VP/SVP Credit Quant Top tier investment bank i...

Selby Jennings: Quantitative Research | Equity | New York

Not specified: Selby Jennings: Quantitative Research | Global Equity | New Yor...

Selby Jennings: SVP Model Validation

Not specified: Selby Jennings: SVP Model Validation This top tiered investment...

Selby Jennings: Oil Operations

Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...

Day In a Page

War with Isis: The West needs more than a White Knight

The West needs more than a White Knight

Despite billions spent on weapons, the US has not been able to counter Isis's gruesome tactics, says Patrick Cockburn
Return to Helmand: Private Davey Graham recalls the day he was shot by the Taliban

'The day I was shot by the Taliban'

Private Davey Graham was shot five times during an ambush in 2007 - it was the first, controversial photograph to show the dangers our soldiers faced in Helmand province
Revealed: the best and worst airlines for delays

Revealed: the best and worst airlines for delays

Many flyers are failing to claim compensation to which they are entitled, a new survey has found
The stories that defined 2014: From the Scottish independence referendum to the Ice Bucket Challenge, our writers voice their opinions

The stories that defined 2014

From the Scottish independence referendum to the Ice Bucket Challenge, our writers voice their opinions
Stoke-on-Trent becomes first British city to be classified as 'disaster resilient' by the United Nations

Disaster looming? Now you know where to head...

Which British city has become the first to be awarded special 'resilience' status by the UN?
Finally, a diet that works: Californian pastor's wildly popular Daniel Plan has seen his congregation greatly reduced

Finally, a diet that works

Californian pastor's wildly popular Daniel Plan has seen his congregation greatly reduced
Say it with... lyrics: The power of song was never greater, according to our internet searches

Say it with... lyrics

The power of song was never greater, according to our internet searches
Professor Danielle George: On a mission to bring back the art of 'thinkering'

The joys of 'thinkering'

Professor Danielle George on why we have to nurture tomorrow's scientists today
Monique Roffey: The author on father figures, the nation's narcissism and New Year reflections

Monique Roffey interview

The author on father figures, the nation's narcissism and New Year reflections
Introducing my anti-heroes of 2014

Introducing my anti-heroes of 2014

Their outrageousness and originality makes the world a bit more interesting, says Ellen E Jones
DJ Taylor: Good taste? It's all a matter of timing...

Good taste? It's all a matter of timing...

It has been hard to form generally accepted cultural standards since the middle of the 19th century – and the disintegration is only going to accelerate, says DJ Taylor
Olivia Jacobs & Ben Caplan: 'Ben thought the play was called 'Christian Love'. It was 'Christie in Love' - about a necrophiliac serial killer'

How we met

Olivia Jacobs and Ben Caplan
Bill Granger recipes: Our chef's breakfasts will revitalise you in time for the New Year

Bill Granger's healthy breakfasts

Our chef's healthy recipes are perfect if you've overindulged during the festive season
Transfer guide: From Arsenal to West Ham - what does your club need in the January transfer window?

Who does your club need in the transfer window?

Most Premier League sides are after a striker, but here's a full run down of the ins and outs that could happen over the next month
The Last Word: From aliens at FA to yak’s milk in the Tour, here’s to 2015

Michael Calvin's Last Word

From aliens at FA to yak’s milk in the Tour, here’s to 2015